Research Topics
| Hicham SkaliSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali
Department of Medicine, Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
Am J Kidney Dis 61:238-46. 2013..We intended to describe Hb level trends over time with no or minimal administration of erythropoiesis-stimulating agents...- Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equationHicham Skali
Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
Am Heart J 162:548-54. 2011..We aimed to assess the incremental prognostic accuracy of eGFR(CKD-EPI) versus eGFR(MDRD) in subjects at increased risk for CV disease... - Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic StudyAnil Verma
Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
JACC Cardiovasc Imaging 1:582-91. 2008..This study sought to understand prognostic implications of increased baseline left ventricular (LV) mass and geometric patterns in a high risk acute myocardial infarction... - High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialRachel E Anderson
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
Am Heart J 155:706-11. 2008..We examined characteristics, cardiovascular outcomes, and the influence of risk factors on outcomes in young survivors of AMI... 
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02445, USA
Circulation 112:3738-44. 2005..Nevertheless, once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk in heart failure patients...- Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic studyJens Jakob Thune
Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
J Am Soc Echocardiogr 19:1462-5. 2006..Regional assessment might be a more sensitive predictor of outcome than global assessment in patients with acute MI... - Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experienceKent Stephenson
Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Heart Rhythm 4:308-13. 2007.... - Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failureScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 116:1482-7. 2007.... - Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experienceNagesh S Anavekar
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Am Soc Echocardiogr 19:28-33. 2006..The prognostic significance of MPI is less clear for cardiovascular (CV) events after myocardial infarction (MI) among individuals at high risk with depressed left ventricular (LV) systolic function... - Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskirenAmil M Shah
Division of Cardiovascular Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02445, USA
Eur J Heart Fail 14:185-92. 2012..We assessed the relationship between diabetes and cardiac structure and function following myocardial infarction (MI) and whether diabetes influences the effect of direct renin inhibition on change in left ventricular (LV) size... - Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
Circulation 116:627-36. 2007..However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality... - Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno
Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 59:1785-95. 2012..The aim of this study was to explore the relationship between baseline resting heart rate and outcomes in patients with chronic heart failure (HF) according to baseline left ventricular ejection fraction (LVEF) and cardiac rhythm... - Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic studyScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
Am Heart J 150:257-62. 2005..Angiotensin-converting enzyme (ACE) inhibition attenuates ventricular remodeling and improves ventricular function in heart failure patients. Vasopeptidase inhibition has shown similar effects in experimental models... - Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialDavid Aguilar
Cardiovascular Division, University of Texas Health Science Center, 6431 Fannin, MSB 1 246, Houston, TX 77030, USA
Circulation 110:1572-8. 2004..A prior diagnosis of diabetes mellitus is associated with adverse outcomes after acute myocardial infarction (MI), but the risk associated with a new diagnosis of diabetes in this setting has not been well defined... - Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni
Brigham and Women s Hospital, Boston, Massachusetts, USA
Eur Heart J 28:326-33. 2007.... - Association of QRS duration and outcomes after myocardial infarction: the VALIANT trialLakshminarayan Yerra
Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
Heart Rhythm 3:313-6. 2006.... - Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experienceHicham Skali
Brigham and Women s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115, USA
Circulation 124:2903-8. 2011..We sought to identify baseline characteristics and postrandomization factors that might explain this association... - Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02445, USA
Am Heart J 162:685-91. 2011..We hypothesized that after high-risk MI, patients with diabetes would demonstrate patterns of remodeling that are suggestive of reduced ventricular compliance and that are associated with an increased risk of death or HF... - Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarctionPowell Jose
Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
J Am Soc Nephrol 17:2886-91. 2006..Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices... - Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarctionAnil Verma
Cardiovascular Division, Ochsner Medical Center, New Orleans, LA, USA
Am Heart J 161:1156-62. 2011..However, the extent to which measures of LV structure and function provide incremental prognostic value over clinical variables in survivors of high-risk myocardial infarction has not been well defined... - Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarctionScott D Solomon
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
Circulation 106:1251-5. 2002..We used data from the Survival and Ventricular Enlargement (SAVE) echocardiographic substudy to test the hypothesis that diabetes was associated with increased LV enlargement after MI... - Prognostic use of echocardiography 1 year after a myocardial infarctionHicham Skali
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Am Heart J 150:743-9. 2005..4, 95% CI 8.2-46.0) in follow-up. CONCLUSIONS: In a stable population of survivors of MI, impaired LV and RV function at 1 year after MI are independently and additively predictive of increased risk of HF or death... - Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
Circulation 110:2180-3. 2004..We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program... - Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
Circulation 111:3411-9. 2005.... - Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunctionScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
Eur Heart J 32:1227-34. 2011.... - Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or bothAnne Catherine Pouleur
Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 122:597-602. 2010.... - Variable impact of combining fatal and nonfatal end points in heart failure trialsHicham Skali
Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 114:2298-303. 2006..Longer-duration trials have a more predictable increase in events than short RCTs. Trial duration must be considered when composite end points are used during the design and interpretation of HF RCTs... - Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolismTudor Scridon
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Am J Cardiol 96:303-5. 2005..Patients with elevated troponin and right ventricular enlargement are at significantly greater risk for death after PE than patients with only 1 or with neither adverse prognostic marker... - Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarctionDavid Aguilar
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Am Coll Cardiol 43:2015-21. 2004..We assessed the influence of alcohol intake on the development of symptomatic heart failure (HF) in patients with left ventricular (LV) dysfunction after a myocardial infarction (MI)... 
Mortality rates in trials of subjects with type 2 diabetesEbrahim Barkoudah
Cardiovascular Division, Dana Farber Cancer Institute, Boston, MA E B, H S, S D S, M A P General Medicine Division, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA E B
J Am Heart Assoc 1:8-15. 2012..In randomized controlled trials (RCTs) of subjects with type 2 diabetes mellitus, mortality rates vary substantially. We sought to examine the inclusion and exclusion criteria of these RCTs to explore relationships with mortality...- Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)Nagesh S Anavekar
Department of Cardiology, Austin Health, University of Melbourne, Melbourne, Australia
Am J Cardiol 101:607-12. 2008..53 (95% CI 1.24 to 1.88) increased risk of fatal and nonfatal CV outcomes. In conclusion, decreased right ventricular systolic function is a major risk factor for death, sudden death, HF, and stroke after MI... - Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative studyNagesh S Anavekar
Cardiovascular Clinical Trials Unit, Austin Health, University of Melbourne, Melbourne, Australia
Echocardiography 24:452-6. 2007..Hence, quantitative estimation of RV function has proven difficult in clinical practice... - Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress testSara L Partington
Noninvasive Cardiovascular Imaging Program, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
J Nucl Cardiol 19:970-8. 2012..Our aim was to study the feasibility and safety of regadenoson injection at peak ETT for submaximal heart rate (HR) response... - Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activityJustina C Wu
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Eur Heart J 31:1088-97. 2010..This study analysed the cardiovascular manifestations of a cohort of Fabry patients, and sought to define relationships between disease severity, alphagal activity, and cardiac abnormalities... - Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarctionLeonardo A M Zornoff
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 39:1450-5. 2002..3% to 29.2%; p = 0.006). CONCLUSIONS: Right ventricular function is an independent predictor of death and the development of HF in patients with LV dysfunction after MI...